- Home
- » Tags
- » Cancer Research UK
Top View
- FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
- Modifying Chemotherapy for the Older Patient
- Onxeo Establishes Scientific Advisory Board with International Experts in DNA-Targeting
- 2019-2020 Aacr Research Grant Recipients
- Activating Transcription Factor-2 (ATF2)
- Welcome Agenda
- Phase 1 Trial of Mov18, a First-In-Class Ige Antibody Therapy for Cancer
- Profile of Tomas Lindahl, Paul Modrich, and Aziz Sancar, 2015 Nobel Laureates in Chemistry
- Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic NATICK, Mass., June
- Cancer Treatment
- Bristol Cancer
- Cancer Research Uk Lung Cancer Centre of Excellence at Manchester and Ucl
- Temozolomide
- Brain Tumour Research
- The Francis Crick Institute
- Steeped in Science
- LAM-561 in Addition to Radiation Therapy and Temozolomide for Glioblastoma
- Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase
- Cancer Research UK (BCCR0001) April 2021 Relating to Brain Tumour and Childhood Cancer Research
- Knowledge of Potential Harms and Benefits of Tamoxifen Among Women Considering Breast Cancer Preventive Therapy
- Discovery Without Boundaries
- Cancer Research: the Lessons to Learn from COVID-19 Chris Bailey1, James R.M
- Tracerx Consortium Members
- Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-Wide Infrastructure for Multicentre Clinical
- 5-Fluorouracil Incorporated Into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity Qian An, Peter Robins, Tomas Lindahl, and Deborah E
- Cancer Network Newsletter July - August 2018
- DNA Repair – Providing Chemical Stability for Life
- Cancer Research UK
- Two Phase II Trials of Temozolomide with Interferon-&Alpha
- Patient Consent Form
- Onedotzero Deliver a Dynamic Online Donations Driver for Cancer Research UK
- Professor Tom Connors and the Development of Novel Cancer Therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK
- Francis Crick Institute
- Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies In
- A Cancer Research UK First Time in Human Phase I Trial of IMA950
- Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART- NET)